Figure 2.

Follow-up of patients who discontinued anti-PD-1, University Hospital of Bordeaux, 2019. Of the 65 patients included, 38% (n = 25) discontinued treatment for CR, 18% (n = 12) for PR or SD, and 43% (n = 28) because of AEs.